论文部分内容阅读
当前评价抗凝血酶Ⅲ(ATⅢ)作用的对照研究均应用固定剂量的ATⅢ,难以满足严重脓毒症患者个体治疗的需要。德国研究人员假设根据ATⅢ活性指导其对严重外科脓毒症的治疗能产生更好的效果。他们使用某重症加强治疗病房(ICU)数据库的资料进行了一项回顾性分析研究。研究中共纳入545例术后脓毒症患者,通过多参数综合累积模型、Cox累积风险模型以及倾向性评分调整法,观察ATⅢ治疗对患者输血次数和预后的影响。其中230例患者持续调整ATⅢ剂量使其活性达到
The current evaluation of the role of antithrombin Ⅲ (AT Ⅲ) control study using a fixed dose of AT Ⅲ, it is difficult to meet the needs of patients with severe sepsis treatment. German researchers hypothesized that AT III activity would guide its treatment of severe surgical sepsis to produce better results. They conducted a retrospective analysis using data from a critical intensive care unit (ICU) database. A total of 545 postoperative sepsis patients were enrolled in this study. The effects of AT Ⅲ treatment on the number of transfusions and prognosis of patients were observed by means of cumulative multi-parameter model, Cox cumulative risk model and propensity score adjustment. Among them, 230 patients continued to adjust AT Ⅲ dose to achieve their activity